Electricity-assisted cancer therapies: nanotechnology, electrochemotherapy, and machine learning

Fadlil[1*], Tri Wahono[2], Lina Handayani[3], Hendril Satrian P[4]
[1,2]Master Program of Electrical Engineering, Fac. of Industrial Tech, Universitas Ahmad Dahlan, Yogyakarta, Indonesia
[3]Master Program of Public Health, Fac. of Public Health, Universitas Ahmad Dahlan, Yogyakarta, Indonesia
[2,4]Embedded System and Power Electronics Research Group, Yogyakarta, Indonesia
[1]2307057007@webmail.uad.ac.id*, [2]2307057010@webmail.uad.ac.id, [3]lina.handayani@ikm.uad.ac.id
[4]lfriyan220@gmail.com
[*]*Corresponding author*

Abstract

Electricity-assisted cancer therapies, including nanotechnology and electrochemotherapy (ECT), have emerged as promising approaches in oncology. Nanotechnology delivers anticancer drugs to tumor sites precisely, improving efficacy and reducing side effects. ECT uses electric pulses to increase cancer cell drug uptake, making them more treatable. Electricity-assisted cancer therapies increasingly employ machine learning algorithms to analyze complex data, optimize treatment protocols, and predict patient outcomes. Nanotechnology has shown promise in improving therapy efficacy and targeting. Researchers can precisely deliver drugs to cancerous cells using nanoparticles, minimizing tissue damage. Nanoparticles' unique properties enable customization to meet treatment needs, improving patient outcomes and treatment success. With fewer side effects, ECT kills cancer cells more effectively. It uses electric pulses to increase cancer cell uptake of chemotherapy drugs, improving treatment outcomes. More research is necessary to optimize electric pulses and chemotherapy drugs to maximize the therapeutic potential of ECT. Machine learning algorithms for electricity-assisted cancer therapies have the potential to revolutionize cancer treatment. Researchers can improve existing therapies and develop patient-specific approaches by using artificial intelligence to analyze massive amounts of data and optimize treatment protocols.

Keywords: Electricity-assisted cancer therapies, nanotechnology, electrochemotherapy, machine learning, electric pulses

1. INTRODUCTION

Electricity-assisted cancer therapies have emerged as promising approaches in the field of oncology, offering innovative ways to target and treat cancer cells [1]. Nanotechnology, electrochemotherapy (ECT), and machine learning have played significant roles in advancing these therapies [2]–[13]. Nanotechnology enables the precise delivery of anticancer agents to tumor sites, enhancing treatment effectiveness while minimizing side effects. ECT, on the other hand, utilizes electric pulses to increase drug uptake by cancer cells, making them more susceptible to treatment. Furthermore, machine learning algorithms have been increasingly utilized to analyze complex data sets, optimize treatment protocols, and predict patient outcomes in electricity-assisted cancer therapies. By integrating these cutting-edge technologies, researchers are paving the way for more personalized and efficient cancer treatment options. In this paper, we will explore the recent advancements and applications of machine learning in conjunction with nanotechnology and ECT to improve cancer treatment outcomes.

In the realm of cancer therapies, understanding the background information is crucial for developing innovative and effective treatments. Traditional cancer therapies such as surgery, chemotherapy, and radiation have been the cornerstone of cancer treatment for decades. However, these methods can be invasive, have harmful side effects, and may not always be effective in treating all types of cancer. This has led to the exploration of new approaches, including electricity-assisted therapies. Nanotechnology, electrochemotherapy, and machine learning have emerged as promising fields in cancer treatment. Nanotechnology offers the ability to target cancer cells specifically, minimizing damage to healthy tissues [14]–[19]. Electrochemotherapy utilizes electric pulses to enhance the effectiveness of chemotherapy drugs [20]. Additionally, machine learning algorithms provide opportunities for personalized treatment plans based on individual patient data, optimizing outcomes and minimizing adverse effects [4], [5], [12], [13], [21]. These innovative therapies represent the next frontier in cancer treatment, offering hope for improved patient outcomes and quality of life.

Moreover, the realm of electricity-assisted cancer therapies is rapidly expanding with the integration of cutting-edge technologies such as nanotechnology, electrochemotherapy, and machine learning. Nanotechnology has opened up new avenues for targeted drug delivery and enhanced imaging techniques in cancer treatment. Electrochemotherapy, on the other hand, leverages electric pulses to increase the permeability of cancer cells, allowing for better drug uptake [2]–[13], [22]. Furthermore, these therapies generate vast amounts of data that machine learning algorithms analyze, enabling personalized treatment strategies and

Received: Mar 24, 2024; Revised: June 23, 2024; Accepted: Jul 1, 2024

predictive modeling for patient outcomes. The synergy of these approaches holds great promise for revolutionizing cancer care by improving treatment efficacy, reducing side effects, and ultimately prolonging patient survival rates. As researchers continue to explore the potential of these electricity-assisted therapies, the future of cancer treatment looks increasingly bright and transformative.

In the field of cancer treatment, nanotechnology plays a crucial role in revolutionizing the way we approach the disease. People are increasingly using nanoparticles for targeted drug delivery, which enables the precise delivery of therapeutic agents to cancer cells while minimizing damage to healthy tissues. Specific ligands can functionalize these nanoparticles to actively target cancer cells, thereby enhancing treatment efficacy and minimizing adverse side effects. Furthermore, nanotechnology enables the development of novel imaging techniques that can provide real-time monitoring of tumor responses to treatments, aiding in personalized medicine approaches. Additionally, we can engineer nanoparticles to simultaneously deliver multiple therapeutic modalities, such as chemotherapy drugs and immunotherapies, enhancing treatment outcomes and overcoming drug resistance mechanisms. The potential of nanotechnology in cancer treatment is vast, offering new possibilities for improved patient outcomes and survival rates [2], [3], [6]–[11], [23].

Electrochemotherapy (ECT) is a promising cancer treatment that combines chemotherapy with electric pulses to enhance drug delivery into tumor cells. The process starts with chemotherapeutic agents like bleomycin being given. Next, electroporation is used to make the cell membranes more permeable, which lets the drugs work better inside the cells. The electric pulses create temporary pores in the cell membrane, facilitating the uptake of the drugs and leading to increased cytotoxic effects on the cancer cells. This approach has shown significant improvements in tumor response rates and overall patient outcomes in various types of cancer, including melanoma and breast cancer. Furthermore, studies have demonstrated that ECT is well-tolerated with minimal side effects, making it a promising option for cancer treatment [3], [24]–[35]. We need further research and clinical studies to optimize the technique and expand its application to different cancer types [20].

Furthermore, it is impossible to overstate the importance of machine learning in healthcare, especially when it comes to electricity-assisted cancer therapies. Machine learning algorithms can analyze vast amounts of patient data to identify patterns and trends that may not be immediately apparent to human researchers. This capability is crucial in developing personalized treatment plans for cancer patients, as it allows for the prediction of treatment outcomes based on individual characteristics and responses to therapy. By integrating machine learning with nanotechnology and electrochemotherapy, healthcare providers can enhance the precision and effectiveness of cancer treatment strategies. Additionally, machine learning can aid in image processing, improve diagnostic imaging accuracy, and enable the early detection of cancerous growths. This study presents a review of electricity-assisted cancer therapies from the viewpoints of nanotechnology, electrochemotherapy, and machine learning.

2. NANOTECHNOLOGY IN CANCER TREATMENT

In the field of cancer treatment, nanotechnology offers promising advancements in enhancing the efficacy and targeting of therapies [2], [3], [6]–[11], [23]. By utilizing nanoparticles, researchers can deliver drugs with increased precision to cancerous cells, minimizing damage to healthy tissues. Nanoparticles can be designed to bypass biological barriers and selectively accumulate in tumors, maximizing therapeutic effects while minimizing side effects [20]. Additionally, the unique properties of nanoparticles, such as their high surface area-to-volume ratio and potential for surface modification, allow for customization to meet specific treatment needs. This personalized approach holds great potential in improving patient outcomes and overall treatment success rates. As research in nanotechnology continues to evolve, its integration with electricity-assisted cancer therapies, such as electrochemotherapy, is poised to revolutionize the way we combat cancer.

2.1. Definition and principles of nanotechnology

Nanotechnology, a field that involves the manipulation of materials on an atomic or molecular scale, holds immense promise in the realm of cancer therapy. The principles of nanotechnology revolve around the design, characterization, production, and application of structures, devices, and systems by controlling shape and size at the nanometer scale. This allows for the development of nanoparticles that can target specific cancer cells, deliver therapeutic agents directly to tumors, and enhance treatment efficacy while minimizing side effects [2], [3], [6]–[11], [23]. Key principles of nanotechnology include the ability to engineer materials at the nanoscale, exploit unique properties at this scale, and create multifunctional platforms for cancer diagnosis and treatment. Ultimately, nanotechnology holds the potential to revolutionize cancer treatment by providing targeted and personalized therapies that can improve patient outcomes while reducing systemic toxicities.

2.2. Applications of nanotechnology in cancer therapy

Furthermore, nanotechnology has shown great promise in revolutionizing cancer therapy by providing targeted drug delivery and enhanced imaging capabilities. Nanoparticles such as liposomes, dendrimers, and quantum dots can be engineered to specifically target cancer cells, reducing systemic toxicity and increasing treatment efficacy. Additionally, nanoparticles can be functionalized with ligands that bind to specific receptors on cancer cells, allowing for precise drug delivery. These nanoparticles can also be loaded with chemotherapeutic drugs, genes, or imaging agents, further enhancing their therapeutic potential. Some nanoparticles have even been designed to respond to external stimuli, releasing their payload upon exposure to specific triggers such as light, heat, or magnetic fields, a concept known as smart nanoparticles [36]. Overall, nanotechnology holds immense potential in advancing cancer therapy by improving drug delivery, reducing side effects, and enhancing treatment outcomes [2], [3], [6]–[11], [23].

2.3. Nanoparticles for targeted drug delivery

The development of nanoparticles for targeted drug delivery has shown promising results in the field of cancer treatment. These nanoparticles have the potential to revolutionize the way we administer chemotherapy drugs by specifically targeting cancer cells while minimizing damage to healthy tissues. By utilizing nanotechnology, researchers can design nanoparticles with specific characteristics such as size, shape, and surface chemistry to enhance their accumulation at the tumor site through passive or active targeting mechanisms. Furthermore, these nanoparticles can be loaded with anti-cancer drugs or therapeutic agents to improve their efficacy and reduce systemic side effects. Studies have demonstrated the feasibility and effectiveness of nanoparticle-based drug delivery systems in preclinical and clinical settings, showing enhanced therapeutic outcomes and improved patient survival rates. The combination of nanotechnology, electrochemotherapy, and machine learning offers a promising approach for more personalized and efficient cancer treatment strategies [2], [9], [14], [15], [17], [18], [37].

2.4. Role of nanotechnology in enhancing treatment efficacy

Nanotechnology has emerged as a pivotal player in revolutionizing cancer treatment efficacy through innovative approaches such as cell membrane-coated nanoparticles (CMNPs) and device-assisted Hyperthermic Intravesical Chemotherapy (HIVEC). As evidenced by the meta-analysis conducted, HIVEC has showcased promising outcomes in reducing recurrence and progression of non-muscle invasive bladder cancer post-bladder tumor resection. Meanwhile, the review on CMNPs accentuates their potential in enhancing drug delivery precision, immune system circumvention, and targeted recognition, thereby bolstering treatment efficacy. These advancements underscore the transformative impact of nanotechnology in augmenting therapeutic outcomes by overcoming limitations associated with conventional therapies. By harnessing the unique capabilities of nanotechnology, researchers are poised to redefine the landscape of cancer treatment through targeted drug delivery mechanisms and innovative therapeutic modalities within the realm of electricity-assisted cancer therapies [2], [3], [6]–[11], [23].

2.5. Challenges and future prospects of nanotechnology in cancer treatment

As nanotechnology continues to advance, it brings both challenges and promising prospects for cancer treatment. One of the main challenges is ensuring the targeted delivery of nano-based therapeutics to tumor sites while minimizing off-target effects. Achieving this precise delivery remains a significant hurdle in translating nanomedicine into clinical practice. Additionally, the potential toxicity of certain nanoparticles poses a safety concern that must be addressed through rigorous testing and evaluation. Despite these obstacles, the future of nanotechnology in cancer treatment looks bright [2], [3], [6]–[11], [23]. Researchers are exploring innovative ways to enhance the efficacy of nanomedicines through the integration of machine learning algorithms for personalized treatment regimens. By harnessing the power of artificial intelligence, nanotechnology holds great promise in revolutionizing cancer therapy and improving patient outcomes [36], [38]–[40].

3. ELECTROCHEMOTHERAPY (ECT)

In recent years, Electrochemotherapy (ECT) has emerged as a promising treatment modality for cancer patients. By combining chemotherapy drugs with the application of electric pulses to the tumor site, ECT has shown increased efficacy in killing cancer cells while minimizing systemic side effects. One key advantage of ECT is its ability to enhance the uptake of chemotherapeutic agents into cancer cells, thereby improving treatment outcomes. Additionally, ECT has been found to be effective in treating a variety of solid tumors, including melanoma, breast cancer, and head and neck cancers. Despite its promising results, further research is needed to optimize the parameters of electric pulses and chemotherapy drugs used in ECT to maximize its therapeutic potential. Integrating machine learning algorithms into ECT protocols could provide a valuable tool for personalized treatment strategies and improved patient outcomes. This innovative approach holds great promise in advancing the field of cancer therapy and improving the quality of life for cancer patients [3], [24]–[35], [41].

3.1. Understanding electrochemotherapy and its mechanism

One key aspect of electricity-assisted cancer therapies is electrochemotherapy (ECT), which combines chemotherapy with the application of electric pulses to enhance drug uptake by cancer cells. This novel approach has shown promising results in various cancer types, including melanoma and breast cancer. The mechanism of ECT involves the formation of pores in the cell membrane through electroporation, allowing chemotherapy agents to enter the cells more efficiently and increase their cytotoxic effects. The electric pulses used in ECT also induce cell death through various mechanisms, including reactive oxygen species production and disruption of intracellular structures [41]. Understanding the intricate interplay between electric pulses and chemotherapy agents in ECT is crucial for optimizing treatment protocols and improving patient outcomes in the field of cancer therapeutics [3]–[13], [24]–[35].

3.2. Comparison of ECT with traditional cancer treatments

In considering the comparison of Electrochemotherapy (ECT) with traditional cancer treatments, it is essential to recognize the unique benefits and limitations of each approach. ECT, which combines chemotherapy with the application of electric pulses to enhance drug uptake by cancer cells, offers a promising alternative for patients who may not respond well to standard treatments. Research has shown that ECT can improve treatment efficacy, reduce side effects, and enhance patient outcomes in certain cases. However, while ECT shows potential in specific scenarios, such as treating superficial tumors or recurrent cancers, it may not be suitable for all types of cancer or advanced stages of the disease. Traditional cancer treatments, such as surgery, radiation therapy, and systemic chemotherapy, continue to play a crucial role in managing various cancer types and stages. Each approach has its place in the overall treatment paradigm, highlighting the importance of personalized medicine and multidisciplinary collaboration in cancer care [1], [15]–[18], [30], [42].

3.3. Clinical applications and effectiveness of ECT

In the realm of electricity-assisted cancer therapies, Electroconvulsive Therapy (ECT) has shown promising results in certain clinical applications. ECT involves the administration of electric currents to the brain, typically used as a treatment for severe depression. However, recent studies have explored its potential in treating certain types of cancers, such as pancreatic cancer and glioblastoma multiforme. ECT works by inducing apoptotic cell death and disrupting the tumor microenvironment, making it a valuable addition to the arsenal of cancer treatment modalities. Despite its effectiveness, ECT is often reserved for cases where traditional therapies have been ineffective, due to its potential side effects and the necessity for anesthesia during the procedure. Future research utilizing machine learning algorithms to optimize ECT parameters and predict treatment outcomes could further enhance its clinical efficacy. Further studies are needed to elucidate the full potential of ECT in cancer treatment and to address the challenges associated with its implementation [2], [18], [31]–[33].

3.4. Side effects and safety considerations of ECT

In the comprehensive exploration of electricity-assisted cancer therapies, including Electrochemotherapy (ECT), considerations of side effects and safety aspects are paramount in ensuring the effective and safe application of these innovative treatments. Addressing the potential off-target effects and pharmacological promiscuity, particularly in the context of multidimensional treatment approaches, underscores the need for meticulous monitoring and assessment of adverse reactions. In the context of ECT for cancer therapy, it is essential to evaluate not only the targeted cytotoxic effects but also the impact on cardiovascular ion channels and potential systemic effects as discussed by [43]. These insights emphasize the complex interplay between treatment efficacy and safety profiles, necessitating a thorough understanding of the polypharmacological aspects of ECT and the adoption of vigilant strategies to mitigate side effects and enhance patient outcomes.

3.5. Ongoing research and advancements in ECT technology

Recent advancements in ECT technology have shown promising results in the field of cancer treatment. Researchers are continually refining the delivery methods and enhancing the efficacy of ECT through the integration of nanotechnology and machine learning algorithms. These innovations allow for targeted delivery of electric pulses to cancer cells, minimizing damage to healthy tissue. Nanoparticles loaded with chemotherapeutic agents can increase the specificity of treatment, while machine learning algorithms are being used to optimize pulse parameters and treatment protocols based on individual patient characteristics [44]. These personalized approaches are revolutionizing cancer therapy, offering new hope for patients with previously untreatable tumors. As ongoing research in ECT technology continues to evolve, the potential for more effective and less invasive cancer treatments is becoming increasingly evident.

4. MACHINE LEARNING IN ELECTRICITY-ASSISTED CANCER THERAPIES

Recent advancements in machine learning have revolutionized the field of electricity-assisted cancer therapies, particularly in the realm of nanotechnology and electrochemotherapy [4], [5], [12], [13], [21]. By analyzing large datasets of patient outcomes and treatment responses, machine learning algorithms can now predict which patients are most likely to benefit from these innovative therapies. Additionally, machine learning techniques have been utilized to enhance image processing in real-time during treatment procedures, allowing for more precise targeting of cancer cells while minimizing damage to healthy tissue. This integration of machine learning with electricity-assisted cancer therapies has the potential to significantly improve treatment outcomes and pave the way for personalized medicine in oncology. As more research is conducted in this rapidly evolving field, the role of machine learning is poised to become increasingly central to the development and optimization of cutting-edge cancer treatment modalities [36].

4.1. Overview of machine learning in healthcare

Machine learning has emerged as a powerful tool in healthcare, specifically in the field of electricity-assisted cancer therapies. By harnessing the capabilities of machine learning algorithms, healthcare professionals have been able to analyze vast amounts of data to identify patterns, make predictions, and improve treatment outcomes for cancer patients. In the context of nanotechnology, machine learning has been instrumental in designing more effective nanomedicines for targeted drug delivery. Additionally, in the realm of electrochemotherapy (ECT), machine learning algorithms have been employed to optimize treatment parameters and predict response to therapy based on patient-specific characteristics. Furthermore, image processing techniques powered by machine learning have enhanced the accuracy of cancer diagnosis and treatment planning by enabling the extraction of valuable information from medical imaging data [36]. The integration of machine learning in electricity-assisted cancer therapies represents a promising avenue for advancing personalized medicine and improving patient care.

4.2. Role of machine learning in personalized cancer treatment

Machine learning has shown great promise in advancing personalized cancer treatment by enabling the analysis of vast amounts of patient data to tailor therapies more effectively. By utilizing algorithms that can identify patterns in genetic mutations, treatment responses, and patient outcomes, machine learning algorithms can help predict which treatments are most likely to be successful for individual patients. For example, machine learning models have been used to classify tumor subtypes and predict drug sensitivities, allowing for more targeted and efficient treatment strategies. Furthermore, machine learning techniques have been integrated into image processing algorithms to improve the accuracy of tumor detection and monitoring. These advancements hold the potential to revolutionize cancer treatment by enabling oncologists to make more informed decisions based on individual patient characteristics, ultimately leading to better outcomes and higher survival rates [41].

4.3. Applications of machine learning in nanotechnology for cancer therapies

Recent advancements in machine learning have opened up new possibilities for the development of personalized cancer therapies utilizing nanotechnology. Machine learning algorithms can analyze vast amounts of data to identify patterns and predict outcomes, making them invaluable tools in optimizing treatment strategies for individual patients. In the field of nanotechnology for cancer therapies, machine learning can assist in designing nanoparticles with specific properties for targeted drug delivery. By leveraging machine learning techniques, researchers can overcome challenges such as optimizing drug release kinetics and minimizing off-target effects. Furthermore, machine learning algorithms can analyze imaging data to track the distribution of nanoparticles in real-time, providing valuable insights into their efficacy [36]. The integration of machine learning with nanotechnology holds great promise for improving the effectiveness and safety of cancer treatments, bringing us closer to more personalized and efficient therapies.

4.4. Machine learning algorithms for predicting treatment outcomes

The intersection of machine learning algorithms and cancer treatment outcomes represents a cutting-edge development in the realm of precision medicine. Recent advancements in AI, particularly in the context of nanotechnology and electrochemotherapy, showcase the potential for predictive models to revolutionize treatment strategies for cancer patients. By leveraging intricate data sets, including genetic profiles and imaging data, machine learning algorithms hold the promise of accurately forecasting treatment responses and guiding clinicians in selecting the most effective therapies [39]. These algorithms exhibit a remarkable capacity to distinguish between benign and malignant lesions, enhancing diagnostic accuracy and facilitating personalized treatment plans [40]. Furthermore, the integration of AI into clinical practice not only streamlines the early detection of cancer but also optimizes therapeutic interventions, potentially improving patient outcomes and reducing mortality rates in individuals battling this formidable disease.

4.5. Challenges and ethical considerations in implementing machine learning in cancer treatment

The rapid advancements in machine learning have paved the way for innovative applications in electricity-assisted cancer therapies, particularly in the realms of nanotechnology, nanomedicine, electrochemotherapy (ECT), and image processing. However, the integration of machine learning in cancer treatment presents notable challenges and ethical considerations that warrant careful examination. Regulatory oversight and data privacy concerns are paramount, as the utilization of AI algorithms for personalized treatment and clinical decision-making requires robust frameworks to ensure patient confidentiality and data security [38]. Transparency and interpretability of machine learning algorithms are essential to foster trust between healthcare professionals and AI systems, enabling informed decision-making and accountability. Additionally, ethical considerations surrounding the equitable access to AI-driven therapies and the potential implications on patient autonomy must be addressed to uphold ethical standards in cancer treatment innovation. Embracing machine learning in cancer therapy necessitates a thoughtful and comprehensive approach that navigates these challenges to maximize the benefits of this transformative technology [38].

5. RESULTS AND DISCUSSION

The electricity-assisted cancer therapies discussed in this study highlights the diverse and promising approaches being developed to combat cancer. Nanotechnology, with its ability to deliver targeted treatments and enhance imaging techniques, has shown great potential in improving cancer therapy outcomes. Electrochemotherapy (ECT) offers a non-invasive and effective treatment option for various types of tumors, making it a valuable addition to the existing arsenal of cancer therapies [31]–[34]. Machine learning algorithms have also been increasingly utilized in optimizing treatment strategies, predicting patient responses, and advancing personalized medicine in the realm of cancer treatment [4], [5], [12], [13], [21]. As the field of electricity-assisted cancer therapies continues to evolve, incorporating these cutting-edge technologies and approaches will undoubtedly lead to better outcomes for patients [1]. Further research and clinical trials will be vital in fully realizing the potential of these innovative strategies for cancer treatment [22].

Recent studies have shed light on the significant impact of machine learning interventions in enhancing end-of-life care conversations for cancer patients, as demonstrated by the randomized clinical trial involving 20,506 patients with cancer [7], [12], [27]. The implementation of machine learning mortality predictions coupled with behavioral nudges led to a substantial increase in serious illness conversations (SICs) and a decrease in end-of-life systemic therapy rates, highlighting the potential of technology-driven approaches to improve patient outcomes. Additionally, investigations into splicing factors have unveiled crucial insights into the role of RNA-binding proteins in cancer progression and prognosis. Through comprehensive bioinformatics analyses, specific splicing factors were identified as potential prognostic indicators in liver hepatocellular carcinoma, underscoring the intricate regulatory mechanisms in cancer-specific contexts [21]. These findings emphasize the evolving landscape of cancer research, showcasing the integration of advanced technologies like machine learning and molecular biology to advance precision medicine strategies in cancer treatment [1], [6], [9], [10], [31].

Moreover, the integration of nanotechnology, electrochemotherapy, and machine learning in cancer treatment has significant implications for the future of oncology. Nanotechnology enables targeted drug delivery systems that can enhance the efficacy of cancer treatments while minimizing side effects on healthy tissues. Electrochemotherapy, on the other hand, utilizes electric pulses to effectively deliver chemotherapy drugs into cancer cells, offering a less invasive treatment option with reduced toxicity [13], [16], [28]. Additionally, machine learning algorithms can analyze vast amounts of data to personalize treatment plans based on individual patient characteristics, leading to more precise and effective therapies. By combining these technologies, clinicians can optimize cancer treatment strategies, improving patient outcomes and potentially revolutionizing the field of oncology. Further research and clinical trials are needed to fully explore the potential benefits and challenges of integrating these innovative approaches in cancer care [36].

Advancements in electricity-assisted cancer therapies have paved the way for innovative treatment approaches that hold significant promise for the future. The integration of machine learning algorithms in these therapies has allowed for more precise diagnostics and personalized treatment plans. Nanotechnology-based platforms play a crucial role in delivering therapeutic agents directly to tumor cells, enhancing treatment efficacy while minimizing off-target effects. ECT has emerged as a promising modality that combines the cytotoxic effects of electric pulses with chemotherapeutic agents, resulting in improved outcomes for patients with various types of cancer. Additionally, image processing technologies have further improved the accuracy of treatment delivery and monitoring. Moving forward, future directions in this field may focus on the development of targeted delivery systems, optimization of treatment protocols, and the exploration of novel combinations of therapies to enhance therapeutic outcomes. These advancements have the potential to revolutionize cancer treatment strategies and significantly impact patient care [41].

6. CONCLUSION

The integration of machine learning algorithms in electricity-assisted cancer therapies, particularly in the realms of nanotechnology, nanomedicine, electrochemotherapy (ECT), and image processing, holds great promise for revolutionizing cancer treatment. By harnessing the power of artificial intelligence to analyze vast amounts of data and optimize treatment protocols, researchers can potentially enhance the effectiveness of existing therapies and develop novel targeted approaches tailored to individual patients. Furthermore, the combination of machine learning with advancements in nanotechnology offers new avenues for precise drug delivery and real-time monitoring of treatment response. As the field continues to evolve, collaborations between engineers, physicists, biologists, and clinicians will be crucial in translating these innovative technologies into clinical practice, ultimately improving patient outcomes and survival rates in the fight against cancer. Such interdisciplinary efforts highlight the importance of merging cutting-edge research with practical healthcare solutions. In conclusion, the advancements in electricity-assisted cancer therapies have shown promising results in improving treatment outcomes and patient survival rates. However, there is still much to be explored and developed in this field. By further researching and developing nanotechnology, electrochemotherapy, and machine learning applications, we can continue to enhance the efficacy and precision of these therapies. Future studies could focus on optimizing drug delivery systems using nanotechnology, refining electrochemotherapy protocols to maximize tumor destruction while minimizing side effects, and implementing machine learning algorithms for personalized treatment plans based on individual patient characteristics. Collaborative efforts between researchers, clinicians, and industry partners will be crucial in pushing the boundaries of innovation and ultimately improving the standard of care for cancer patients worldwide. It is imperative that we continue to invest in research and development in these areas to advance the field of electricity-assisted cancer therapies.

REFERENCES

[1] S. Zhong *et al.*, “Electricity-Assisted Cancer Therapy: From Traditional Clinic Applications to Emerging Methods Integrated with Nanotechnologies,” *Adv. NanoBiomed Res.*, vol. 3, no. 3, 2023, doi: 10.1002/anbr.202200143.
[2] C. M. Castelló, M. T. de Carvalho, A. F. Bakuzis, S. G. Fonseca, and M. P. Miguel, “Local tumour nanoparticle thermal therapy: A promising immunomodulatory treatment for canine cancer,” *Vet. Comp. Oncol.*, vol. 20, no. 4, pp. 752–766, 2022, doi: 10.1111/vco.12842.
[3] M. Breton and L. M. Mir, “Microsecond and nanosecond electric pulses in cancer treatments,” *Bioelectromagnetics*, vol. 33, no. 2, pp. 106–123, 2012, doi: 10.1002/bem.20692.
[4] A. Gazendam and M. Ghert, “What’s New in Musculoskeletal Tumor Surgery,” *J. Bone Jt. Surg.*, vol. 105, no. 24, pp. 1929–1936, 2023, doi: 10.2106/JBJS.23.00833.
[5] N. J. Holl, H.-J. Lee, and Y.-W. Huang, “Evolutionary timeline of genetic delivery and gene therapy,” *Curr. Gene Ther.*, vol. 21, no. 2, pp. 89–111, 2021, doi: 10.2174/1566523220666201208092517.
[6] A. Singh, “Novel nanolipoidal systems for the management of skin cancer,” *Recent Patents Drug Deliv. Formul.*, vol. 14, no. 2, pp. 108–125, 2020, doi: 10.2174/1872211314666200817115700.
[7] P. Yang, X. Zhi, Y. Xu, L. Qian, and Z. Dai, “Nanomedicines enhance minimally invasive therapy of pancreatic cancer,” *Nano Today*, vol. 51, 2023, doi: 10.1016/j.nantod.2023.101891.
[8] S. Kwiatkowski *et al.*, “Photodynamic therapy – mechanisms, photosensitizers and combinations,” *Biomed. Pharmacother.*, vol. 106, pp. 1098–1107, 2018, doi: 10.1016/j.biopha.2018.07.049.
[9] A. Mohd Itoo, B. Ghosh, and S. Biswas, “Recent advancements in Nanotechnology-Mediated Platinum-Based cancer therapy,” *Coord. Chem. Rev.*, vol. 508, 2024, doi: 10.1016/j.ccr.2024.215796.
[10] V. Sansone, R. Frairia, M. Brañes, P. Romeo, M. G. Catalano, and R. C. Applefield, “Current Applications and Future Prospects of Extracorporeal Shockwave Therapy,” *Transl. Res. Biomed.*, vol. 6, pp. 140–157, 2018, doi: 10.1159/000485072.
[11] M. C. F. Simões, J. J. S. Sousa, and A. A. C. C. Pais, “Skin cancer and new treatment perspectives: A review,” *Cancer Lett.*, vol. 357, no. 1, pp. 8–42, 2015, doi: 10.1016/j.canlet.2014.11.001.
[12] V. Ahern, “Selecting patients for proton beam therapy,” *J. Med. Radiat. Sci.*, vol. 68, no. 1, pp. 2–3, 2021, doi: 10.1002/jmrs.454.
[13] M. C. Lo Greco *et al.*, “Relapsing High—Grade Glioma from Peritumoral Zone: Critical Review of Radiotherapy

Treatment Options," *Brain Sci.*, vol. 12, no. 4, 2022, doi: 10.3390/brainsci12040416.
[14] J. Fu *et al.*, "Synergistic therapy using doxorubicin-loading and nitric oxide-generating hollow prussian blue nanoparticles with photoacoustic imaging potential against breast cancer," *Int. J. Nanomedicine*, vol. 16, pp. 6003–6016, 2021, doi: 10.2147/IJN.S327598.
[15] Y. Tang *et al.*, "Bifidobacterium bifidum-mediated specific delivery of nanoparticles for tumor therapy," *Int. J. Nanomedicine*, vol. 16, pp. 4643–4659, 2021, doi: 10.2147/IJN.S315650.
[16] J. Liu *et al.*, "In situ Injection of pH-and Temperature-Sensitive Nanomaterials Increases Chemo-Photothermal Efficacy by Alleviating the Tumor Immunosuppressive Microenvironment," *Int. J. Nanomedicine*, vol. 17, pp. 2661–2678, 2022, doi: 10.2147/IJN.S367121.
[17] P. Xu *et al.*, "Therapeutic effect of doxorubicin-chlorin e6-loaded mesoporous silica nanoparticles combined with ultrasound on triple-negative breast cancer," *Int. J. Nanomedicine*, vol. 15, pp. 2659–2668, 2020, doi: 10.2147/IJN.S243037.
[18] E. Niemelä *et al.*, "Nanoparticles carrying fingolimod and methotrexate enables targeted induction of apoptosis and immobilization of invasive thyroid cancer," *Eur. J. Pharm. Biopharm.*, vol. 148, pp. 1–9, 2020, doi: 10.1016/j.ejpb.2019.12.015.
[19] Y. Okamoto *et al.*, "Inhibitory effects and gene expression analysis of chemotherapeutic photodynamic therapy by using a liposomally formulated indocyanine green derivative," *Photodiagnosis Photodyn. Ther.*, vol. 39, 2022, doi: 10.1016/j.pdpdt.2022.102961.
[20] L. Mohammad-Hadi and M. Mohammad-Hadi, *Applications of Minimally Invasive Nanomedicine-Based Therapies in 3D in Vitro Cancer Platforms*. Morgan \& Claypool, 2020. [Online]. Available: https://books.google.co.id/books?id=E-4JzgEACAAJ
[21] M. Yang, J. Liu, P. Kim, and X. Zhou, "Study of prognostic splicing factors in cancer using machine learning approaches.," *Hum. Mol. Genet.*, 2024.
[22] W. B. Pope, Ed., *Glioma Imaging*. Cham: Springer International Publishing, 2020. doi: 10.1007/978-3-030-27359-0.
[23] S. H. Cho and S. Krishnan, Eds., *Cancer Nanotechnology*. CRC Press, 2016. doi: 10.1201/b14049.
[24] A. E. Spiliotis *et al.*, "Evaluation of Electrochemotherapy with Bleomycin in the Treatment of Colorectal Hepatic Metastases in a Rat Model," *Cancers (Basel).*, vol. 15, no. 5, 2023, doi: 10.3390/cancers15051598.
[25] A. Ottlakan *et al.*, "Clinical considerations of bleomycin based electrochemotherapy with variable electrode geometry electrodes for inoperable, deep-seated soft tissue sarcomas," *Bioelectrochemistry*, vol. 148, 2022, doi: 10.1016/j.bioelechem.2022.108220.
[26] M. Tellado *et al.*, "Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma," *Vaccines*, vol. 11, no. 6, 2023, doi: 10.3390/vaccines11061033.
[27] F. Morgese, F. DE FEUDIS, P. Balercia, and R. Berardi, "Potential dual synergy between electrochemotherapy and sequence of immunotherapies in metastatic melanoma: A case report," *Mol. Clin. Oncol.*, vol. 18, no. 2, 2023, doi: 10.3892/mco.2023.2604.
[28] L. Cevolani *et al.*, "Is the association of electrochemotherapy and bone fixation rational in patients with bone metastasis?," *J. Surg. Oncol.*, vol. 128, no. 1, pp. 125–133, 2023, doi: 10.1002/jso.27247.
[29] C. Di Prata *et al.*, "Efficacy of Electrochemotherapy in Breast Cancer Patients of Different Receptor Status: The INSPECT Experience," *Cancers (Basel).*, vol. 15, no. 12, 2023, doi: 10.3390/cancers15123116.
[30] P. Lyons, D. Polini, K. Russell-Ryan, and A. J. P. Clover, "High-Frequency Electroporation and Chemotherapy for the Treatment of Cutaneous Malignancies: Evaluation of Early Clinical Response," *Cancers (Basel).*, vol. 15, no. 12, 2023, doi: 10.3390/cancers15123212.
[31] I. Barca, F. Ferragina, E. Kallaverja, A. Arrotta, and M. G. Cristofaro, "Electrochemotherapy as an Effective Alternative in the Treatment of Local Advanced Oral Squamous Cell Carcinoma: A Retrospective Analysis of Treated Cases," *Int. J. Environ. Res. Public Health*, vol. 20, no. 6, 2023, doi: 10.3390/ijerph20065170.
[32] M. B. Bendix, A. Houston, P. F. Forde, and E. Brint, "Defining optimal parameters to maximize the effect of electrochemotherapy on lung cancer cells whilst preserving the integrity of immune cells," *Bioelectrochemistry*, vol. 148, 2022, doi: 10.1016/j.bioelechem.2022.108257.
[33] A. Balevičiūtė *et al.*, "High-Frequency Nanosecond Bleomycin Electrochemotherapy and its Effects on Changes in the Immune System and Survival," *Cancers (Basel).*, vol. 14, no. 24, 2022, doi: 10.3390/cancers14246254.
[34] M. M. M. Rangel, L. C. M. Linhares, K. D. de Oliveira, D. O. H. Suzuki, F. H. Maglietti, and A. B. de Nardi, "Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs," *Sci. Rep.*, vol. 13, no. 1, 2023, doi: 10.1038/s41598-023-45433-4.
[35] J. Heinzelmann, S. Hecht, A. R. Vogt, U. Siebolts, P. Kaatzsch, and A. Viestenz, "Repetitive Bleomycin-Based Electrochemotherapy Improves Antitumor Effectiveness in 3D Tumor Models of Conjunctival Melanoma," *J. Clin. Med.*, vol. 12, no. 3, 2023, doi: 10.3390/jcm12031087.
[36] F. Dilnawaz and A. K. Behura, *Artificial Intelligence Based Cancer Nanomedicine: Diagnostics, Therapeutics and Bioethics*. Bentham Science Publishers, 2022. [Online]. Available: https://books.google.co.id/books?id=1a91EAAAQBAJ
[37] Y. Çapan, A. Sahin, and H. Tonbul, *Drug Delivery with Targeted Nanoparticles: In Vitro and In Vivo Evaluation Methods*. Jenny Stanford Publishing, 2021. [Online]. Available: https://books.google.co.id/books?id=YihHEAAAQBAJ
[38] V. Mehta, "Artificial Intelligence in Medicine: Revolutionizing Healthcare for Improved Patient Outcomes," *J. Med. Res. Innov.*, 2023.
[39] I. Stevens, "The Epistemological Consequences of Artificial Intelligence, Precision Medicine, and Implantable

Brain-Computer Interfaces," *Voices Bioeth.*, 2024.

[40] Z. Gandhi *et al.*, "Artificial Intelligence and Lung Cancer: Impact on Improving Patient Outcomes," *Cancers (Basel).*, vol. 15, 2023.

[41] M. R. Meijerink, H. J. Scheffer, and G. Narayanan, Eds., *Irreversible Electroporation in Clinical Practice*. Cham: Springer International Publishing, 2018. doi: 10.1007/978-3-319-55113-5.

[42] S. T. Kee, J. Gehl, and E. W. Lee, Eds., *Clinical Aspects of Electroporation*. New York, NY: Springer New York, 2011. doi: 10.1007/978-1-4419-8363-3.

[43] J. Peters, "Polypharmacology in drug discovery," 2012.

[44] K. Takahata, *Advances in Micro/Nano Electromechanical Systems and Fabrication Technologies*. IntechOpen, 2013.